We are live on ! Find out more
ELDN icon

Eledon Pharmaceuticals
ELDN

33 hedge funds and large institutions have $12.7M invested in Eledon Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

21.96% more ownership

Funds ownership: 45.35% → 67.31% (+22%)

10% more funds holding

Funds holding: 30 → 33 (+3)

14% less capital invested

Capital invested by funds: $14.7M → $12.7M (-$2.02M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $12K

Holders
33
Holders Change
+3
Holders Change %
+10%
% of All Funds
0.52%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
10
Reduced
6
Closed
3
Calls
–
Puts
$12K
Net Calls
-$12K
Net Calls Change
-$26K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$4.17M
2
AC
Armistice Capital
New York
+$3.84M
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$570K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$105K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$84.4K

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$2.87M
2
BlackRock
BlackRock
New York
-$50.6K
3
Citadel Advisors
Citadel Advisors
Florida
-$48.1K
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$42.4K
5
SFG
SVB Financial Group
Texas
-$18.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$5.93M +$4.17M +2,000,000 +86%
AC
2
Armistice Capital
New York
$2.52M +$3.84M +1,842,803 New
Vanguard Group
3
Vanguard Group
Pennsylvania
$931K – – –
WP
4
Woodline Partners
California
$708K – – –
Ensign Peak Advisors
5
Ensign Peak Advisors
Utah
$607K – – –
Royal Bank of Canada
6
Royal Bank of Canada
Ontario, Canada
$374K +$570K +273,345 New
CM
7
CM Management
Florida
$322K +$6 +3 +0%
IC
8
Ikarian Capital
Texas
$304K – – –
Geode Capital Management
9
Geode Capital Management
Massachusetts
$232K +$84.4K +40,499 +31%
JE
10
JMAC Enterprises
Pennsylvania
$110K +$53.2K +25,503 +47%
Renaissance Technologies
11
Renaissance Technologies
New York
$83K +$58.8K +28,200 +88%
ISL
12
Ingalls & Snyder LLC
New York
$70K – – –
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$69.2K +$105K +50,502 New
State Street
14
State Street
Massachusetts
$61.2K – – –
Millennium Management
15
Millennium Management
New York
$58.9K +$63.4K +30,397 +241%
Northern Trust
16
Northern Trust
Illinois
$41.2K – – –
BlackRock
17
BlackRock
New York
$38.8K -$50.6K -24,266 -46%
Two Sigma Advisers
18
Two Sigma Advisers
New York
$31.5K -$4.38K -2,100 -8%
BFM
19
Boothbay Fund Management
New York
$30.2K – – –
SFG
20
SVB Financial Group
Texas
$24.7K -$18.6K -8,917 -33%
VF
21
Virtu Financial
New York
$24K +$36.8K +17,675 New
Mercer Global Advisors
22
Mercer Global Advisors
Colorado
$23K – – –
Jane Street
23
Jane Street
New York
$21.6K +$32.9K +15,783 New
Charles Schwab
24
Charles Schwab
California
$20.5K – – –
V
25
Veritable
Delaware
$17.9K – – –
1
2

ELDN Hedge Fund Activity: Q2 2023 in Review

33 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q2 2023, worth a combined $12.7M — down 14% from $14.7M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new ELDN positions and 3 closed out — a net gain of 3 holders — while 10 added to existing stakes and 6 trimmed.

The largest buyer was BVF Inc, adding an estimated $4.17M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $2.87M sold.

  • 33 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q2 2023, up from 30 in Q1 2023.
  • Funds reported $12.7M of Eledon Pharmaceuticals stock for Q2 2023, down 14% quarter-over-quarter.
  • 6 funds opened new Eledon Pharmaceuticals positions in Q2 2023 and 3 closed out, a net change of +3 holders.
  • The largest Eledon Pharmaceuticals buyer in Q2 2023 was BVF Inc, an estimated $4.17M added.
  • The largest Eledon Pharmaceuticals seller in Q2 2023 was Cormorant Asset Management, an estimated $2.87M sold.

Based on aggregated 13F filings for Q2 2023.